Endocrine-Related Cancer

References

1. ↵
   1. Akli S &
   2. Keyomarsi K

   2004 Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Research 6 188–191doi:10.1186/bcr905.
2. ↵
   1. Anido J,
   2. Scaltriti M,
   3. Serra JJB,
   4. Josefat BS,
   5. Todo FR,
   6. Baselga J &
   7. Arribas J

   2006 Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO Journal 25 3234–3244doi:10.1038/sj.emboj.7601191.
3. ↵
   AnonymousTamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative GroupLancet 351 1998 1451–1467doi:10.1016/S0140-6736(97)11423-4.
4. ↵
   AnonymousEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet 365 2005 1687–1717doi:10.1016/S0140-6736(05)66544-0.
5. ↵
   1. de Azambuja E,
   2. Cardoso F,
   3. de Castro G Jr.,
   4. Colozza M,
   5. Mano MS,
   6. Durbecq V,
   7. Sotiriou C,
   8. Larsimont D,
   9. Piccart-Gebhart MJ &
   10. Paesmans M

   2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. British Journal of Cancer 96 1504–1513doi:10.1038/sj.bjc.6603756.
6. ↵
   1. Barbareschi M,
   2. Pelosio P,
   3. Caffo O,
   4. Buttitta F,
   5. Pellegrini S,
   6. Barbazza R,
   7. Dalla Palma P,
   8. Bevilacqua G &
   9. Marchetti A

   1997 Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. International Journal of Cancer 74 171–174doi:10.1002/(SICI)1097-0215(19970422)74:2<171::AID-IJC5>3.0.CO;2-W.
7. ↵
   1. Bardin A,
   2. Boulle N,
   3. Lazennec G,
   4. Vignon F &
   5. Pujol P

   2004 Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocrine-Related Cancer 11 537–551doi:10.1677/erc.1.00800.
8. ↵
   1. Bartlett JM,
   2. Munro AF,
   3. Dunn JA,
   4. McConkey C,
   5. Jordan S,
   6. Twelves CJ,
   7. Cameron DA,
   8. Thomas J,
   9. Campbell FM,
   10. Rea DW
   11. et al.

   2010 Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncology 11 266–274doi:10.1016/S1470-2045(10)70006-1.
9. ↵
   1. Bièche I,
   2. Olivi M,
   3. Noguès C,
   4. Vidaud M &
   5. Lidereau R

   2002 Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. British Journal of Cancer 86 580–586doi:10.1038/sj.bjc.6600109.
10. ↵
    1. Bilalović N,
    2. Vranić S,
    3. Basić H,
    4. Tatarević A &
    5. Selak I

    2005 Immunohistochemical evaluation of cyclin D1 in breast cancer. Croatian Medical Journal 46 382–388.
11. ↵
    1. Board RE,
    2. Wardley AM,
    3. Dixon JM,
    4. Armstrong AC,
    5. Howell S,
    6. Renshaw L,
    7. Donald E,
    8. Greystoke A,
    9. Ranson M,
    10. Hughes A
    11. et al.

    2010 Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Research and Treatment 120 461–467doi:10.1007/s10549-010-0747-9.
12. ↵
    1. Bogaerts J,
    2. Cardoso F,
    3. Buyse M,
    4. Braga S,
    5. Loi S,
    6. Harrison JA,
    7. Bines J,
    8. Mook S,
    9. Decker N,
    10. Ravdin P
    11. et al.

    2006 Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nature Clinical Practice. Oncology 3 540–551doi:10.1038/ncponc0591.
13. ↵
    1. Bortner DM &
    2. Rosenberg MP

    1997 Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Molecular and Cellular Biology 17 453–459.
14. ↵
    1. Brown LA,
    2. Hoog J,
    3. Chin SF,
    4. Tao Y,
    5. Zayed AA,
    6. Chin K,
    7. Teschendorff AE,
    8. Quackenbush JF,
    9. Marioni JC,
    10. Leung S
    11. et al.

    2008 ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genetics 40 806–807(author reply 810–812)doi:10.1038/ng0708-806.
15. ↵
    1. Buckley MF,
    2. Sweeney KJ,
    3. Hamilton JA,
    4. Sini RL,
    5. Manning DL,
    6. Nicholson RI,
    7. deFazio A,
    8. Watts CK,
    9. Musgrove EA &
    10. Sutherland RL

    1993 Expression and amplification of cyclin genes in human breast cancer. Oncogene 8 2127–2133.
16. ↵
    1. Buyse M,
    2. Loi S,
    3. van 't Veer L,
    4. Viale G,
    5. Delorenzi M,
    6. Glas AM,
    7. d'Assignies MS,
    8. Bergh J,
    9. Lidereau R,
    10. Ellis P
    11. et al.

    2006 Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. Journal of the National Cancer Institute 98 1183–1192doi:10.1093/jnci/djj329.
17. ↵
    1. Byar DP,
    2. Sears ME &
    3. McGuire WL

    1979 Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. European Journal of Cancer 15 299–310doi:10.1016/0014-2964(79)90041-0.
18. ↵
    1. Catarino R,
    2. Ferreira MM,
    3. Rodrigues H,
    4. Coelho A,
    5. Nogal A,
    6. Sousa A &
    7. Medeiros R

    2008 Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA and Cell Biology 27 415–421doi:10.1089/dna.2008.0744.
19. ↵
    1. Chang J,
    2. Ormerod M,
    3. Powles TJ,
    4. Allred DC,
    5. Ashley SE &
    6. Dowsett M

    2000a Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89 2145–2152doi:10.1002/1097-0142(20001201)89:11<2145::AID-CNCR1>3.0.CO;2-S.
20. ↵
    1. Chang J,
    2. Powles TJ,
    3. Allred DC,
    4. Ashley SE,
    5. Makris A,
    6. Gregory RK,
    7. Osborne CK &
    8. Dowsett M

    2000b Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clinical Cancer Research 6 616–621.
21. ↵
    1. Cheang MCU,
    2. Chia SK,
    3. Voduc D,
    4. Gao D,
    5. Leung S,
    6. Snider J,
    7. Watson M,
    8. Davies S,
    9. Bernard PS,
    10. Parker JS
    11. et al.

    2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute 101 736–750doi:10.1093/jnci/djp082.
22. ↵
    1. Colleoni M,
    2. Viale G,
    3. Zahrieh D,
    4. Pruneri G,
    5. Gentilini O,
    6. Veronesi P,
    7. Gelber RD,
    8. Curigliano G,
    9. Torrisi R,
    10. Luini A
    11. et al.

    2004 Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clinical Cancer Research 10 6622–6628doi:10.1158/1078-0432.CCR-04-0380.
23. ↵
    1. Cristofanilli M,
    2. Budd GT,
    3. Ellis MJ,
    4. Stopeck A,
    5. Matera J,
    6. Miller MC,
    7. Reuben JM,
    8. Doyle GV,
    9. Allard WJ,
    10. Terstappen LW
    11. et al.

    2004 Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine 321 781–791doi:10.1056/NEJMoa040766.
24. ↵
    1. Cuzick J,
    2. Dowsett M,
    3. Wale C,
    4. Salter J,
    5. Quinn E,
    6. Zabaglo L,
    7. Howell A,
    8. Buzdar A &
    9. Forbes J

    2009 Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score – results from TransATAC. Cancer Research 69 74doi:10.1158/0008-5472.SABCS-09-74.
25. ↵
    1. Desmedt C,
    2. Giobbie-Hurder A,
    3. Neven P,
    4. Paridaens R,
    5. Christiaens MR,
    6. Smeets A,
    7. Lallemand F,
    8. Haibe-Kains B,
    9. Viale G,
    10. Gelber RD
    11. et al.

    2009 The gene expression grade index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Medical Genomics 2 40doi:10.1186/1755-8794-2-40.
26. ↵
    1. Dowsett M,
    2. Cuzick J,
    3. Wale C,
    4. Howell T,
    5. Houghton J &
    6. Baum M

    2005a Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. Journal of Clinical Oncology 23 7512–7517doi:10.1200/JCO.2005.01.4829.
27. ↵
    1. Dowsett M,
    2. Ebbs SR,
    3. Dixon JM,
    4. Skene A,
    5. Griffith C,
    6. Boeddinghaus I,
    7. Salter J,
    8. Detre S,
    9. Hills M,
    10. Ashley S
    11. et al.

    2005b Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer – a study from the IMPACT trialists. Journal of Clinical Oncology 23 2477–2492doi:10.1200/JCO.2005.07.559.
28. ↵
    1. Dowsett M,
    2. Smith IE,
    3. Ebbs SR,
    4. Dixon JM,
    5. Skene A,
    6. Griffith C,
    7. Boeddinghaus I,
    8. Salter J,
    9. Detre S,
    10. Hills M
    11. et al.

    2005c Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clinical Cancer Research 11 951s–958s.
29. ↵
    1. Dowsett M,
    2. Houghton J,
    3. Iden C,
    4. Salter J,
    5. Farndon J,
    6. A'Hern R,
    7. Sainsbury R &
    8. Baum M

    2006a Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Annals of Oncology 17 818–826doi:10.1093/annonc/mdl016.
30. ↵
    1. Dowsett M,
    2. Smith IE,
    3. Ebbs SR,
    4. Dixon JM,
    5. Skene A,
    6. Griffith C,
    7. Boeddinghaus I,
    8. Salter J,
    9. Detre S,
    10. Hills M
    11. et al.

    2006b Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clinical Cancer Research 12 1024s–1030sdoi:10.1158/1078-0432.CCR-05-2127.
31. ↵
    1. Dowsett M,
    2. Goldhirsch A,
    3. Hayes DF,
    4. Senn HJ,
    5. Wood W &
    6. Viale G

    2007a International web-based consultation on priorities for translational breast cancer research. Breast Cancer Research 9 R81doi:10.1186/bcr1798.
32. ↵
    1. Dowsett M,
    2. Smith IE,
    3. Ebbs SR,
    4. Dixon JM,
    5. Skene A,
    6. A'Hern R,
    7. Salter J,
    8. Detre S,
    9. Hills M &
    10. Walsh G

    2007b Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. Journal of the National Cancer Institute 99 167–170doi:10.1093/jnci/djk020.
33. ↵
    1. Dowsett M,
    2. Allred C,
    3. Knox J,
    4. Quinn E,
    5. Salter J,
    6. Wale C,
    7. Cuzick J,
    8. Houghton J,
    9. Williams N,
    10. Mallon E
    11. et al.

    2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. Journal of Clinical Oncology 26 1059–1065doi:10.1200/JCO.2007.12.9437.
34. ↵
    1. Dowsett M,
    2. Procter M,
    3. McCaskill-Stevens W,
    4. de Azambuja E,
    5. Dafni U,
    6. Rueschoff J,
    7. Jordan B,
    8. Dolci S,
    9. Abramovitz M,
    10. Stoss O
    11. et al.

    2009 Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial. Journal of Clinical Oncology 27 2962–2969doi:10.1200/JCO.2008.19.7939.
35. ↵
    1. Dowsett M,
    2. Cuzick J,
    3. Wale C,
    4. Forbes J,
    5. Mallon EA,
    6. Salter J,
    7. Quinn E,
    8. Dunbier A,
    9. Baum M,
    10. Buzdar A
    11. et al.

    2010 Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. Journal of Clinical Oncology 28 1829–1834doi:10.1200/JCO.2009.24.4798.
36. ↵
    1. Dressler LG,
    2. Berry DA,
    3. Broadwater G,
    4. Cowan D,
    5. Cox K,
    6. Griffin S,
    7. Miller A,
    8. Tse J,
    9. Novotny D,
    10. Persons DL
    11. et al.

    2005 Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. Journal of Clinical Oncology 23 4287–4297doi:10.1200/JCO.2005.11.012.
37. ↵
    1. Elledge RM,
    2. Green S,
    3. Pugh R,
    4. Allred DC,
    5. Clark GM,
    6. Hill J,
    7. Ravdin P,
    8. Martino S &
    9. Osborne CK

    2000 Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. International Journal of Cancer 89 111–117doi:10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W.
38. ↵
    1. Enmark E,
    2. Pelto-Huikko M,
    3. Grandien K,
    4. Lagercrantz S,
    5. Lagercrantz J,
    6. Fried G,
    7. Nordenskjöld M &
    8. Gustafsson JA

    1997 Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. Journal of Clinical Endocrinology and Metabolism 82 4258–4265doi:10.1210/jc.82.12.4258.
39. ↵
    1. Faneyte IF,
    2. Schrama JG,
    3. Peterse JL,
    4. Remijnse PL,
    5. Rodenhuis S &
    6. van de Vijver MJ

    2003 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. British Journal of Cancer 88 406–412doi:10.1038/sj.bjc.6600749.
40. ↵
    1. Fehm T,
    2. Solomayer EF,
    3. Meng S,
    4. Tucker T,
    5. Lane N,
    6. Wang J &
    7. Gebauer G

    2005 Methods for isolating circulating epithelial cells and criteria for their classification as carcinoma cells. Cytotherapy 7 171–185doi:10.1080/14653240510027082.
41. ↵
    1. Gennari A,
    2. Sormani MP,
    3. Pronzato P,
    4. Puntoni M,
    5. Colozza M,
    6. Pfeffer U &
    7. Bruzzi P

    2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. Journal of the National Cancer Institute 100 14–20doi:10.1093/jnci/djm252.
42. ↵
    1. Gerdes J,
    2. Schwab U,
    3. Lemke H &
    4. Stein H

    1983 Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. International Journal of Cancer 31 13–20doi:10.1002/ijc.2910310104.
43. ↵
    1. Gillett C,
    2. Fantl V,
    3. Smith R,
    4. Fisher C,
    5. Bartek J,
    6. Dickson C,
    7. Barnes D &
    8. Peters G

    1994 Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Research 54 1812–1817.
44. ↵
    1. Gillett C,
    2. Smith P,
    3. Gregory W,
    4. Richards M,
    5. Millis R,
    6. Peters G &
    7. Barnes D

    1996 Cyclin D1 and prognosis in human breast cancer. International Journal of Cancer 69 92–99doi:10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-Q.
45. ↵
    1. Goldhirsch A,
    2. Ingle JN,
    3. Gelber RD,
    4. Coates AS,
    5. Thürlimann B &
    6. Senn H-J

    2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of Oncology 20 1319–1329doi:10.1093/annonc/mdp322.
46. ↵
    1. Haerslev T,
    2. Jacobsen GK &
    3. Zedeler K

    1996 Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Research and Treatment 37 101–113doi:10.1007/BF01806492.
47. ↵
    1. Hammond MEF,
    2. Hayes DF,
    3. Dowsett M,
    4. Allred DC,
    5. Hagerty KL,
    6. Badve S,
    7. Fitzgibbons PL,
    8. Francis G,
    9. Goldstein NS,
    10. Hayes M
    11. et al.

    2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of Clinical Oncology 28 2784–2795doi:10.1200/JCO.2009.25.6529.
48. ↵
    1. Harris L,
    2. Fritsche H,
    3. Mennel R,
    4. Norton L,
    5. Ravdin P,
    6. Taube S,
    7. Somerfield MR,
    8. Hayes DF &
    9. Bast RC Jr.

    2007 American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology 25 5287–5312doi:10.1200/JCO.2007.14.2364.
49. ↵
    1. Hayes DF,
    2. Bast RC,
    3. Desch CE,
    4. Fritsche H Jr.,
    5. Kemeny NE,
    6. Jessup JM,
    7. Locker GY,
    8. Macdonald JS,
    9. Mennel RG,
    10. Norton L
    11. et al.

    1996 Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. Journal of the National Cancer Institute 88 1456–1466doi:10.1093/jnci/88.20.1456.
50. ↵
    1. Hayes DF,
    2. Thor AD,
    3. Dressler LG,
    4. Weaver D,
    5. Edgerton S,
    6. Cowan D,
    7. Broadwater G,
    8. Goldstein LJ,
    9. Martino S,
    10. Ingle JN
    11. et al.

    2007 HER2 and response to paclitaxel in node-positive breast cancer. New England Journal of Medicine 357 1496–1506doi:10.1056/NEJMoa071167.
51. ↵
    1. Heneghan HM,
    2. Miller N,
    3. Lowery AJ,
    4. Sweeney KJ,
    5. Newell J &
    6. Kerin MJ

    2010 Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of Surgery 251 499–505doi:10.1097/SLA.0b013e3181cc939f.
52. ↵
    1. Herynk MH &
    2. Fuqua SA

    2004 Estrogen receptor mutations in human disease. Endocrine Reviews 25 869–898doi:10.1210/er.2003-0010.
53. ↵
    1. Holst F,
    2. Stahl PR,
    3. Ruiz C,
    4. Hellwinkel O,
    5. Jehan Z,
    6. Wendland M,
    7. Lebeau A,
    8. Terracciano L,
    9. Al-Kuraya K,
    10. Jänicke F
    11. et al.

    2007 Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nature Genetics 39 655–660doi:10.1038/ng2006.
54. ↵
    1. Hopp TA,
    2. Weiss HL,
    3. Parra IS,
    4. Cui Y,
    5. Osborne CK &
    6. Fuqua SA

    2004 Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clinical Cancer Research 10 7490–7499doi:10.1158/1078-0432.CCR-04-1114.
55. ↵
    1. Horlings HM,
    2. Bergamaschi A,
    3. Nordgard SH,
    4. Kim YH,
    5. Han W,
    6. Noh DY,
    7. Salari K,
    8. Joosse SA,
    9. Reyal F,
    10. Lingjaerde OC
    11. et al.

    2008 ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genetics 40 807–808(author reply 810–812)doi:10.1038/ng0708-807.
56. ↵
    1. Howell A,
    2. Cuzick J,
    3. Baum M,
    4. Buzdar A,
    5. Dowsett M,
    6. Forbes JF,
    7. Hoctin-Boes G,
    8. Houghton J,
    9. Locker GY,
    10. Tobias JS
    11. et al.

    2005 Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 60–62doi:10.1016/S0140-6736(05)74803-0.
57. ↵
    1. Hui R,
    2. Cornish AL,
    3. McClelland RA,
    4. Robertson JF,
    5. Blamey RW,
    6. Musgrove EA,
    7. Nicholson RI &
    8. Sutherland RL

    1996 Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clinical Cancer Research 2 923–928.
58. ↵
    1. Hwang TS,
    2. Han HS,
    3. Hong YC,
    4. Lee HJ &
    5. Paik NS

    2003 Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients. Pathology International 53 74–80doi:10.1046/j.1440-1827.2003.01441.x.
59. ↵
    1. Iorio MV,
    2. Ferracin M,
    3. Liu CG,
    4. Veronese A,
    5. Spizzo R,
    6. Sabbioni S,
    7. Magri E,
    8. Pedriali M,
    9. Fabbri M,
    10. Campiglio M
    11. et al.

    2005 MicroRNA gene expression deregulation in human breast cancer. Cancer Research 65 7065–7070doi:10.1158/0008-5472.CAN-05-1783.
60. ↵
    1. Jares P,
    2. Rey MJ,
    3. Fernández PL,
    4. Campo E,
    5. Nadal A,
    6. Muñoz M,
    7. Mallofré C,
    8. Muntané J,
    9. Nayach I,
    10. Estapé J
    11. et al.

    1997 Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. Journal of Pathology 182 160–166doi:10.1002/(SICI)1096-9896(199706)182:2<160::AID-PATH814>3.0.CO;2-2.
61. ↵
    1. Järvinen TA,
    2. Pelto-Huikko M,
    3. Holli K &
    4. Isola J

    2000 Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. American Journal of Pathology 156 29–35.
62. ↵
    1. Jensen EV,
    2. Cheng G,
    3. Palmieri C,
    4. Saji S,
    5. Mäkelä S,
    6. Van Noorden S,
    7. Wahlström T,
    8. Warner M,
    9. Coombes RC &
    10. Gustafsson JA

    2001 Estrogen receptors and proliferation markers in primary and recurrent breast cancer. PNAS 98 15197–15202doi:10.1073/pnas.211556298.
63. ↵
    1. Jirström K,
    2. Stendahl M,
    3. Rydén L,
    4. Kronblad A,
    5. Bendahl PO,
    6. Stål O &
    7. Landberg G

    2005 Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Research 65 8009–8016doi:10.1158/0008-5472.CAN-05-0746.
64. ↵
    1. Jones RL,
    2. Salter J,
    3. A'Hern R,
    4. Nerurkar A,
    5. Parton M,
    6. Reis-Filho JS,
    7. Smith IE &
    8. Dowsett M

    2009 The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment 116 53–68doi:10.1007/s10549-008-0081-7.
65. ↵
    1. Keyomarsi K &
    2. Pardee AB

    1993 Redundant cyclin overexpression and gene amplification in breast cancer cells. PNAS 90 1112–1116doi:10.1073/pnas.90.3.1112.
66. ↵
    1. Keyomarsi K,
    2. O'Leary N,
    3. Molnar G,
    4. Lees E,
    5. Fingert HJ &
    6. Pardee AB

    1994 Cyclin E, a potential prognostic marker for breast cancer. Cancer Research 54 380–385.
67. ↵
    1. Keyomarsi K,
    2. Tucker SL,
    3. Buchholz TA,
    4. Callister M,
    5. Ding Y,
    6. Hortobagyi GN,
    7. Bedrosian I,
    8. Knickerbocker C,
    9. Toyofuku W,
    10. Lowe M
    11. et al.

    2002 Cyclin E and survival in patients with breast cancer. New England Journal of Medicine 347 1566–1575doi:10.1056/NEJMoa021153.
68. ↵
    1. Koff A,
    2. Giordano A,
    3. Desai D,
    4. Yamashita K,
    5. Harper JW,
    6. Elledge S,
    7. Nishimoto T,
    8. Morgan DO,
    9. Franza BR &
    10. Roberts JM

    1992 Formation and activation of a cyclin E–cdk2 complex during the G₁ phase of the human cell cycle. Science 257 1689–1694doi:10.1126/science.1388288.
69. ↵
    1. Kohler C,
    2. Radpour R,
    3. Barekati Z,
    4. Asadollahi R,
    5. Bitzer J,
    6. Wight E,
    7. Bürki N,
    8. Diesch C,
    9. Holzgreve W &
    10. Zhong XY

    2009 Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Molecular Cancer 8 105doi:10.1186/1476-4598-8-105.
70. ↵
    1. Leygue E,
    2. Dotzlaw H,
    3. Watson PH &
    4. Murphy LC

    1998 Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Research 58 3197–3201.
71. ↵
    1. Liu Y,
    2. Gao H,
    3. Marstrand TT,
    4. Ström A,
    5. Valen E,
    6. Sandelin A,
    7. Gustafsson JA &
    8. Dahlman-Wright K

    2008 The genome landscape of ERalpha- and ERbeta-binding DNA regions. PNAS 105 2604–2609doi:10.1073/pnas.0712085105.
72. ↵
    1. Loi S,
    2. Haibe-Kains B,
    3. Desmedt C,
    4. Lallemand F,
    5. Tutt AM,
    6. Gillet C,
    7. Ellis P,
    8. Harris A,
    9. Bergh J,
    10. Foekens JA
    11. et al.

    2007 Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Journal of Clinical Oncology 25 1239–1246doi:10.1200/JCO.2006.07.1522.
73. ↵
    1. Lopez F,
    2. Belloc F,
    3. Lacombe F,
    4. Dumain P,
    5. Reiffers J,
    6. Bernard P &
    7. Boisseau MR

    1991 Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 12 42–49doi:10.1002/cyto.990120107.
74. ↵
    1. Ma X-J,
    2. Hilsenbeck SG,
    3. Wang W,
    4. Ding L,
    5. Sgroi DC,
    6. Bender RA,
    7. Osborne CK,
    8. Allred DC &
    9. Erlander MG

    2006 The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. Journal of Clinical Oncology 24 4611–4619doi:10.1200/JCO.2006.06.6944.
75. ↵
    1. Ma XJ,
    2. Salunga R,
    3. Dahiya S,
    4. Wang W,
    5. Carney E,
    6. Durbecq V,
    7. Harris A,
    8. Goss P,
    9. Sotiriou C,
    10. Erlander M
    11. et al.

    2008 A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clinical Cancer Research 14 2601–2608doi:10.1158/1078-0432.CCR-07-5026.
76. ↵
    1. Mass RD,
    2. Press MF,
    3. Anderson S,
    4. Cobleigh MA,
    5. Vogel CL,
    6. Dybdal N,
    7. Leiberman G &
    8. Slamon DJ

    2005 Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clinical Breast Cancer 6 240–246doi:10.3816/CBC.2005.n.026.
77. ↵
    1. Matsushime H,
    2. Quelle DE,
    3. Shurtleff SA,
    4. Shibuya M,
    5. Sherr CJ &
    6. Kato JY

    1994 D-type cyclin-dependent kinase activity in mammalian cells. Molecular and Cellular Biology 14 2066–2076.
78. ↵
    1. Matthews J &
    2. Gustafsson JA

    2003 Estrogen signaling: a subtle balance between ER alpha and ER beta. Molecular Interventions 3 281–292doi:10.1124/mi.3.5.281.
79. ↵
    1. Mattie MD,
    2. Benz CC,
    3. Bowers J,
    4. Sensinger K,
    5. Wong L,
    6. Scott GK,
    7. Fedele V,
    8. Ginzinger D,
    9. Getts R &
    10. Haqq C

    2006 Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular Cancer 5 24doi:10.1186/1476-4598-5-24.
80. ↵
    1. McShane LM,
    2. Altman DG,
    3. Sauerbrei W,
    4. Taube SE,
    5. Gion M &
    6. Clark GM

    2005 Reporting recommendations for tumor marker prognostic studies. Journal of Clinical Oncology 23 9067–9072doi:10.1200/JCO.2004.01.0454.
81. ↵
    1. Michalides R,
    2. Hageman P,
    3. van Tinteren H,
    4. Houben L,
    5. Wientjens E,
    6. Klompmaker R &
    7. Peterse J

    1996 A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. British Journal of Cancer 73 728–734.
82. ↵
    1. Musgrove EA,
    2. Hamilton JA,
    3. Lee CS,
    4. Sweeney KJ,
    5. Watts CK &
    6. Sutherland RL

    1993 Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Molecular and Cellular Biology 13 3577–3587.
83. ↵
    1. Muss HB,
    2. Thor AD,
    3. Berry DA,
    4. Kute T,
    5. Liu ET,
    6. Koerner F,
    7. Cirrincione CT,
    8. Budman DR,
    9. Wood WC,
    10. Barcos M
    11. et al.

    1994 c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New England Journal of Medicine 330 1260–1266doi:10.1056/NEJM199405053301802.
84. ↵
    1. Nicholson RI,
    2. McClelland RA,
    3. Finlay P,
    4. Eaton CL,
    5. Gullick WJ,
    6. Dixon AR,
    7. Robertson JF,
    8. Ellis IO &
    9. Blamey RW

    1993 Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European Journal of Cancer 29A 1018–1023doi:10.1016/S0959-8049(05)80215-1.
85. ↵
    1. Nielsen NH,
    2. Arnerlöv C,
    3. Emdin SO &
    4. Landberg G

    1996 Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. British Journal of Cancer 74 874–880.
86. ↵
    1. Omoto Y,
    2. Inoue S,
    3. Ogawa S,
    4. Toyama T,
    5. Yamashita H,
    6. Muramatsu M,
    7. Kobayashi S &
    8. Iwase H

    2001 Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Letters 163 207–212doi:10.1016/S0304-3835(00)00680-7.
87. ↵
    1. Ormandy CJ,
    2. Musgrove EA,
    3. Hui R,
    4. Daly RJ &
    5. Sutherland RL

    2003 Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Research and Treatment 78 323–335doi:10.1023/A:1023033708204.
88. ↵
    1. Paik S,
    2. Shak S,
    3. Tang G,
    4. Kim C,
    5. Baker J,
    6. Cronin M,
    7. Baehner FL,
    8. Walker MG,
    9. Watson D,
    10. Park T
    11. et al.

    2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817–2826doi:10.1056/NEJMoa041588.
89. ↵
    1. Paik S,
    2. Tang G,
    3. Shak S,
    4. Kim C,
    5. Baker J,
    6. Kim W,
    7. Cronin M,
    8. Baehner FL,
    9. Watson D,
    10. Bryant J
    11. et al.

    2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24 3726–3734doi:10.1200/JCO.2005.04.7985.
90. ↵
    1. Paik S,
    2. Kim C &
    3. Wolmark N

    2008 HER2 status and benefit from adjuvant trastuzumab in breast cancer. New England Journal of Medicine 358 1409–1411doi:10.1056/NEJMc0801440.
91. ↵
    1. Park BW,
    2. Kim KS,
    3. Heo MK,
    4. Ko SS,
    5. Hong SW,
    6. Yang WI,
    7. Kim JH,
    8. Kim GE &
    9. Lee KS

    2003 Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis? Breast Cancer Research and Treatment 80 79–85doi:10.1023/A:1024406223619.
92. ↵
    1. Pegram MD,
    2. Konecny G &
    3. Slamon DJ

    2000 The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treatment and Research 103 57–75.
93. ↵
    1. Perou CM,
    2. Sørlie T,
    3. Eisen MB,
    4. van de Rijn M,
    5. Jeffrey SS,
    6. Rees CA,
    7. Pollack JR,
    8. Ross DT,
    9. Johnsen H,
    10. Akslen LA
    11. et al.

    2000 Molecular portraits of human breast tumours. Nature 406 747–752doi:10.1038/35021093.
94. ↵
    1. Reis-Filho JS,
    2. Drury S,
    3. Lambros MB,
    4. Marchio C,
    5. Johnson N,
    6. Natrajan R,
    7. Salter J,
    8. Levey P,
    9. Fletcher O,
    10. Peto J
    11. et al.

    2008 ESR1 gene amplification in breast cancer: a common phenomenon? Nature Genetics 40 809–810(author reply 810–812)doi:10.1038/ng0708-809b.
95. ↵
    1. Rhodes DR,
    2. Yu J,
    3. Shanker K,
    4. Deshpande N,
    5. Varambally R,
    6. Ghosh D,
    7. Barrette T,
    8. Pandey A &
    9. Chinnaiyan AM

    2004 Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. PNAS 101 9309–9314doi:10.1073/pnas.0401994101.
96. ↵
    1. Ring A &
    2. Dowsett M

    2004 Mechanisms of tamoxifen resistance. Endocrine-Related Cancer 11 643–658doi:10.1677/erc.1.00776.
97. ↵
    1. Ring AE,
    2. Smith IE,
    3. Ashley S,
    4. Fulford LG &
    5. Lakhani SR

    2004 Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. British Journal of Cancer 91 2012–2017doi:10.1038/sj.bjc.6602235.
98. ↵
    1. Roger P,
    2. Sahla ME,
    3. Mäkelä S,
    4. Gustafsson JA,
    5. Baldet P &
    6. Rochefort H

    2001 Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Research 61 2537–2541.
99. ↵
    1. Romond EH,
    2. Perez EA,
    3. Bryant J,
    4. Suman VJ,
    5. Geyer CE Jr.,
    6. Davidson NE,
    7. Tan-Chiu E,
    8. Martino S,
    9. Paik S &
    10. Kaufman PA

    2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine 353 1673–1684doi:10.1056/NEJMoa052122.
100. ↵
     1. Rudolph P,
     2. Olsson H,
     3. Bonatz G,
     4. Ratjen V,
     5. Bolte H,
     6. Baldetorp B,
     7. Fernö M,
     8. Parwaresch R &
     9. Alm P

     1999 Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. Journal of Pathology 187 207–216doi:10.1002/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-U.
101. ↵
     1. Scaltriti M,
     2. Rojo F,
     3. Ocaña A,
     4. Anido J,
     5. Guzman M,
     6. Cortes J,
     7. Di Cosimo S,
     8. Matias-Guiu X,
     9. Ramon y Cajal S,
     10. Arribas J
     11. et al.

     2007 Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute 99 628–638doi:10.1093/jnci/djk134.
102. ↵
     1. Seshadri R,
     2. Lee CS,
     3. Hui R,
     4. McCaul K,
     5. Horsfall DJ &
     6. Sutherland RL

     1996 Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clinical Cancer Research 2 1177–1184.
103. ↵
     1. Skliris GP,
     2. Munot K,
     3. Bell SM,
     4. Carder PJ,
     5. Lane S,
     6. Horgan K,
     7. Lansdown MR,
     8. Parkes AT,
     9. Hanby AM,
     10. Markham AF
     11. et al.

     2003 Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. Journal of Pathology 201 213–220doi:10.1002/path.1436.
104. ↵
     1. Skliris GP,
     2. Leygue E,
     3. Curtis-Snell L,
     4. Watson PH &
     5. Murphy LC

     2006 Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. British Journal of Cancer 95 616–626doi:10.1038/sj.bjc.6603295.
105. ↵
     1. Slamon DJ,
     2. Clark GM,
     3. Wong SG,
     4. Levin WJ,
     5. Ullrich A &
     6. McGuire WL

     1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 177–182doi:10.1126/science.3798106.
106. ↵
     1. Smith ML &
     2. Seo YR

     2000 Sensitivity of cyclin E-overexpressing cells to cisplatin/taxol combinations. Anticancer Research 20 2537–2539.
107. ↵
     1. Smith B,
     2. Selby P,
     3. Southgate J,
     4. Pittman K,
     5. Bradley C &
     6. Blair GE

     1991 Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338 1227–1229doi:10.1016/0140-6736(91)92100-G.
108. ↵
     1. Smith I,
     2. Procter M,
     3. Gelber RD,
     4. Guillaume S,
     5. Feyereislova A,
     6. Dowsett M,
     7. Goldhirsch A,
     8. Untch M,
     9. Mariani G,
     10. Baselga J
     11. et al.

     2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 29–36doi:10.1016/S0140-6736(07)60028-2.
109. ↵
     1. Sørlie T,
     2. Perou CM,
     3. Tibshirani R,
     4. Aas T,
     5. Geisler S,
     6. Johnsen H,
     7. Hastie T,
     8. Eisen MB,
     9. van de Rijn M,
     10. Jeffrey SS
     11. et al.

     2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869–10874doi:10.1073/pnas.191367098.
110. ↵
     1. Sørlie T,
     2. Tibshirani R,
     3. Parker J,
     4. Hastie T,
     5. Marron JS,
     6. Nobel A,
     7. Deng S,
     8. Johnsen H,
     9. Pesich R,
     10. Geisler S
     11. et al.

     2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100 8418–8423doi:10.1073/pnas.0932692100.
111. ↵
     1. Sotiriou C &
     2. Pusztai L

     2009 Gene-expression signatures in breast cancer. New England Journal of Medicine 360 790–800doi:10.1056/NEJMra0801289.
112. ↵
     1. Sotiriou C,
     2. Neo S-Y,
     3. McShane LM,
     4. Korn EL,
     5. Long PM,
     6. Jazaeri A,
     7. Martiat P,
     8. Fox SB,
     9. Harris AL &
     10. Liu ET

     2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study. PNAS 100 10393–10398doi:10.1073/pnas.1732912100.
113. ↵
     1. Sotiriou C,
     2. Wirapati P,
     3. Loi S,
     4. Harris A,
     5. Fox S,
     6. Smeds J,
     7. Nordgren H,
     8. Farmer P,
     9. Praz V,
     10. Haibe-Kains B
     11. et al.

     2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute 98 262–272doi:10.1093/jnci/djj052.
114. ↵
     1. Sparano JA

     2006 TAILORx: trial assigning individualized options for treatment (Rx). Clinical Breast Cancer 7 347–350doi:10.3816/CBC.2006.n.051.
115. ↵
     1. Sparano JA &
     2. Paik S

     2008 Development of the 21-gene assay and its application in clinical practice and clinical trials. Journal of Clinical Oncology 26 721–728doi:10.1200/JCO.2007.15.1068.
116. ↵
     1. Speirs V,
     2. Malone C,
     3. Walton DS,
     4. Kerin MJ &
     5. Atkin SL

     1999 Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Research 59 5421–5424.
117. ↵
     1. Stendahl M,
     2. Kronblad A,
     3. Rydén L,
     4. Emdin S,
     5. Bengtsson NO &
     6. Landberg G

     2004 Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. British Journal of Cancer 90 1942–1948doi:10.1038/sj.bjc.6601831.
118. ↵
     1. Ström A,
     2. Hartman J,
     3. Foster JS,
     4. Kietz S,
     5. Wimalasena J &
     6. Gustafsson JA

     2004 Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. PNAS 101 1566–1571doi:10.1073/pnas.0308319100.
119. ↵
     1. Stuart-Harris R,
     2. Caldas C,
     3. Pinder SE &
     4. Pharaoh P

     2008 Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17 323–334doi:10.1016/j.breast.2008.02.002.
120. ↵
     1. Trihia H,
     2. Murray S,
     3. Price K,
     4. Gelber RD,
     5. Golouh R,
     6. Goldhirsch A,
     7. Coates AS,
     8. Collins J,
     9. Castiglione-Gertsch M &
     10. Gusterson BA

     2003 Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors – a surrogate marker? Cancer 97 1321–1331doi:10.1002/cncr.11188.
121. ↵
     1. Umekita Y,
     2. Souda M,
     3. Ohi Y,
     4. Sagara Y,
     5. Rai Y,
     6. Takahama T &
     7. Yoshida H

     2006 Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression. Pathology International 56 423–427doi:10.1111/j.1440-1827.2006.01983.x.
122. ↵
     1. Urruticoechea A,
     2. Smith IE &
     3. Dowsett M

     2005 Proliferation marker Ki-67 in early breast cancer. Journal of Clinical Oncology 23 7212–7220doi:10.1200/JCO.2005.07.501.
123. ↵
     1. van 't Veer LJ,
     2. Dai H,
     3. van de Vijver MJ,
     4. He YD,
     5. Hart AA,
     6. Mao M,
     7. Peterse HL,
     8. van der Kooy K,
     9. Marton MJ,
     10. Witteveen AT
     11. et al.

     2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530–536doi:10.1038/415530a.
124. ↵
     1. Viale G,
     2. Regan MM,
     3. Maiorano E,
     4. Mastropasqua MG,
     5. Dell'Orto P,
     6. Rasmussen BB,
     7. Raffoul J,
     8. Neven P,
     9. Orosz Z,
     10. Braye S
     11. et al.

     2007 Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. Journal of Clinical Oncology 25 3846–3852doi:10.1200/JCO.2007.11.9453.
125. ↵
     1. van de Vijver MJ,
     2. He YD,
     3. van 't Veer LJ,
     4. Dai H,
     5. Hart AA,
     6. Voskuil DW,
     7. Schreiber GJ,
     8. Peterse JL,
     9. Roberts C,
     10. Marton MJ
     11. et al.

     2002 A gene-expression signature as a predictor of survival in breast. New England Journal of Medicine 347 1999–2009doi:10.1056/NEJMoa021967.
126. ↵
     1. Wang QS,
     2. Sabourin CL,
     3. Wang H &
     4. Stoner GD

     1996 Overexpression of cyclin D1 and cyclin E in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesi. Carcinogenesis 17 1583–1588doi:10.1093/carcin/17.8.1583.
127. ↵
     1. Wang Y,
     2. Klijn JG,
     3. Zhang Y,
     4. Sieuwerts AM,
     5. Look MP,
     6. Yang F,
     7. Talantov D,
     8. Timmermans M,
     9. Meijer-van Gelder ME &
     10. Yu J

     2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 671–679doi:10.1016/S0140-6736(05)17947-1.
128. ↵
     1. Wang Z,
     2. Dahiya S,
     3. Provencher H,
     4. Muir B,
     5. Carney E,
     6. Coser K,
     7. Shioda T,
     8. Ma XJ &
     9. Sgroi DC

     2007 The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer. Clinical Cancer Research 13 6327–6334doi:10.1158/1078-0432.CCR-07-0310.
129. ↵
     1. Widakowich C,
     2. Dinh P,
     3. de Azambuja E,
     4. Awada A &
     5. Piccart-Gebhart M

     2008 HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? Anti-Cancer Agents in Medicinal Chemistry 8 488–496doi:10.2174/187152008784533062.
130. ↵
     1. Wingate H,
     2. Puskas A,
     3. Duong M,
     4. Bui T,
     5. Richardson D,
     6. Liu Y,
     7. Tucker SL,
     8. Van Pelt C,
     9. Meijer L,
     10. Hunt K
     11. et al.

     2009 Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle 8 1062–1068.
131. ↵
     1. Wolff AC,
     2. Hammond ME,
     3. Schwartz JN,
     4. Hagerty KL,
     5. Allred DC,
     6. Cote RJ,
     7. Dowsett M,
     8. Fitzgibbons PL,
     9. Hanna WM,
     10. Langer A
     11. et al.

     2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 25 118–145doi:10.1200/JCO.2006.09.2775.
132. ↵
     1. Zwijsen RM,
     2. Wientjens E,
     3. Klompmaker R,
     4. van der Sman J,
     5. Bernards R &
     6. Michalides RJ

     1997 CDK-independent activation of estrogen receptor by cyclin D1. Cell 88 405–415doi:10.1016/S0092-8674(00)81879-6.